Number:

Expires:

response...

Estimated average burden hours per

January 31,

2005

0.5

AMAG PHARMACEUTICALS INC. Form 3 December 22, 2016 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number 3235-0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> KELLEY BRIAN P			2. Date of Event RequiringStatement(Month/Day/Year)		3. Issuer Name and Ticker or Trading Symbol AMAG PHARMACEUTICALS INC. [AMAG]				
(Last)	(First)	(Middle)	12/20/2016)	4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Original Filed(Month/Day/Year)	
C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET (Street)				X Direct Officer				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting	
WALTHAM	, MA (02451						Person Form filed by More than One Reporting Person	
(City)	(State)	(Zip)		Table I - N	Non-Derivat	ive Securit	ies Be	neficially Owned	
1.Title of Securi (Instr. 4)	ity			2. Amount of Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Na Owne (Instr	*	
No securities are beneficially owned			ed 0			D	Â		
Reminder: Repo owned directly c	•		ch class of secu	urities benefici	ially S	EC 1473 (7-02	2)		
	inforn requii	nation conta red to respo	pond to the c ained in this f nd unless th MB control ne	form are not e form displ					

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)
		(Instr. 4)	Price of	Derivative	
			Derivative	Security:	

Edgar Filing: AMAG PHARMACEUTICALS INC. - Form 3

Date Exercisable	Expiration Date	Title	Amount or Number of	Security	Direct (D) or Indirect	
Excicisable	Date		Shares		(I)	
					(Instr. 5)	

Reporting Owners

Reporting Owner Name / Address		Relationships				
	Director	10% Owner	Officer	Other		
KELLEY BRIAN P C/O AMAG PHARMACEUTICALS, INC 1100 WINTER STREET WALTHAM, MA 02451	ÂX	Â	Â	Â		
Signatures						
Nancy R. Smith, attorney-in-fact	2016					

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.